Table 1 Characteristics of people living with HIV on ART at enrollment by HIV support group attendance
Characteristics | All participants (n = 1959) | Did not attend support group (n = 1639) | Attended support group (n = 320) | *p-value |
|---|---|---|---|---|
Study site |  |  |  | < 0.001 |
 Kayunga, Uganda | 218 (11.1%) | 176 (10.7%) | 42 (13.1%) |  |
 South Rift Valley, Kenya | 782 (39.9%) | 625 (38.1%) | 157 (49.1%) |  |
 Kisumu West, Kenya | 391 (20.0%) | 354 (21.6%) | 37 (11.6%) |  |
 Mbeya, Tanzania | 370 (18.9%) | 323 (19.7%) | 47 (14.7%) |  |
 Abuja & Lagos Nigeria | 198 (10.1%) | 161 (9.8%) | 37 (11.6%) |  |
Age (years) |  |  |  | < 0.01 |
 18–29 | 334 (17.0%) | 289 (17.6%) | 45 (14.1%) |  |
 30–39 | 637 (32.5%) | 550 (33.6%) | 87 (27.2%) |  |
 40–49 | 602 (30.7%) | 496 (30.3%) | 106 (33.1%) |  |
 50+ | 386 (19.7%) | 304 (18.5%) | 82 (25.6%) |  |
Sex | Â | Â | Â | 0.80 |
 Male | 857 (43.7%) | 715 (43.6%) | 142 (44.4%) |  |
 Female | 1102 (56.3%) | 924 (56.4%) | 178 (55.6%) |  |
Education | Â | Â | Â | 0.43 |
 None or some primary | 625 (31.9%) | 524 (32.0%) | 101 (31.6%) |  |
 Primary or some secondary | 759 (38.7%) | 643 (39.2%) | 116 (36.3%) |  |
 Secondary and above | 575 (29.4%) | 472 (28.8%) | 103 (32.2%) |  |
Currently employed |  |  |  | < 0.01 |
 No | 1265 (64.6%) | 1081 (66.0%) | 184 (57.5%) |  |
 Yes | 694 (35.4%) | 558 (34.0%) | 136 (42.5%) |  |
Marital status | Â | Â | Â | 0.20 |
 Not married | 837 (42.7%) | 690 (42.1%) | 147 (45.9%) |  |
 Married | 1122 (57.3%) | 949 (57.9%) | 173 (54.1%) |  |
Consume alcohol | Â | Â | Â | 0.12 |
 No | 1638 (83.6%) | 1361 (83.0%) | 277 (86.6%) |  |
 Yes | 321 (16.4%) | 278 (17.0%) | 43 (13.4%) |  |
ART treatment supporter | Â | Â | Â | 0.22 |
 No | 677 (34.6%) | 576 (35.1%) | 101 (31.6%) |  |
 Yes | 1282 (65.4%) | 1063 (64.9%) | 219 (68.4%) |  |
WHO stage at time of HIV diagnosis | Â | Â | Â | 0.20 |
 I | 676 (34.5%) | 582 (35.5%) | 94 (29.4%) |  |
 II | 599 (30.6%) | 486 (29.7%) | 113 (35.3%) |  |
 III | 537 (27.4%) | 448 (27.3%) | 89 (27.8%) |  |
 IV | 98 (5.0%) | 83 (5.1%) | 15 (4.7%) |  |
 Unknown | 49 (2.5%) | 40 (2.4%) | 9 (2.8%) |  |
Duration on ART |  |  |  | < 0.001 |
  < 6 months | 399 (20.4%) | 379 (23.1%) | 20 (6.3%) |  |
 6 months to < 2 years | 406 (20.7%) | 361 (22.0%) | 45 (14.1%) |  |
 2 to < 4 years | 336 (17.2%) | 284 (17.3%) | 52 (16.3%) |  |
 4+ years | 818 (41.8%) | 615 (37.5%) | 203 (63.4%) |  |
ART regimen |  |  |  | < 0.001 |
 AZT/NVP/3TC | 493 (25.2%) | 378 (23.1%) | 115 (35.9%) |  |
 AZT/EFV/3TC | 167 (8.5%) | 141 (8.6%) | 26 (8.1%) |  |
 TDF/NVP/3TC | 173 (8.8%) | 139 (8.5%) | 34 (10.6%) |  |
 PI-based | 135 (6.9%) | 97 (5.9%) | 38 (11.9%) |  |
 TLE | 930 (47.5%) | 830 (50.6%) | 100 (31.3%) |  |
 Other | 61 (3.1%) | 54 (3.3%) | 7 (2.2%) |  |